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Abstract
Background: Procedural pain relief is sub-optimal in infants, especially small and vulnerable ones. Tetracaine gel
4% (Ametop®, Smith-Nephew) provides pain relief in children and larger infants, but its efficacy in smaller infants
and for peripherally inserted central catheters (PICC) remains uncertain. The objective of this trial was to assess
the safety and efficacy of tetracaine gel on the pain response of very low birth weight (VLBW) infants during
insertion of a PICC.
Methods: Medically stable infants greater than or equal to 24 weeks gestation, requiring a non-urgent PICC,
were included. Following randomization and double blinding, 1.1 g of tetracaine or placebo was applied to the skin
for 30 minutes. The PICC was inserted according to a standard protocol. Pain was assessed using the Premature
Infant Pain Profile (PIPP). A 3-point change in the pain score was considered clinically significant, leading to a
sample size of 54 infants, with 90% statistical power. Local skin reactions and immediate adverse cardiorespiratory
events were noted. The primary outcome, PIPP score at 1 minute, was analysed using an independent Student's
t-test.
Results: Fifty-four infants were included, 27 +/- 2 weeks gestation, 916 +/- 292 grams and 6.5 +/- 3.2 days of age.
Baseline characteristics were similar between groups. The mean PIPP score in the first minute was 10.88 in the
treatment group as compared to 11.74 in the placebo group (difference 0.86, 95% CI -1.86, 3.58). Median duration
of crying in non-intubated infants was 181 seconds in the tetracaine group compared to 68 seconds in the placebo
group (difference -78, 95% CI -539, 117). Local skin erythema was observed transiently in 4 infants (3 in the
treatment and 1 in the placebo group). No serious harms were observed.
Conclusion: Tetracaine 4% when applied for 30 minutes was not beneficial in decreasing procedural pain
associated with a PICC in very small infants.
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Background
Infants admitted to neonatal intensive care units (NICUs)
undergo multiple painful procedures throughout their
stay. Those born between 27 and 31 weeks gestation
undergo on average 134 painful procedures within the
first two weeks of life, ranging from 2 to 8 per day [1,2]. A
recent prospective observational study reported a mean of
14.4 painful procedures a day for infants of 25 to 42
weeks gestation [3]. Pain remains under-treated in infants,
particularly those who are preterm. There is a growing
body of evidence suggesting that multiple painful and
stressful events experienced by infants born preterm
induce acute physiological changes and permanent struc-
tural and functional central nervous system changes [4].
This may lead to several long-term sequelae, including
chronic pain and altered neurobehavioral responses to
subsequent pain [4]. Our standard of care at the time this
protocol was written was to use non-pharmacological
interventions, including swaddling and non-nutritive
sucking for painful procedures such as venipuncture, heel
pricks and placement of peripherally inserted central cath-
eters (PICC). More recently, experts have recommended
sucrose and/or local or systemic analgesia before such
procedures [5]. Side effects of systemic analgesics limit
their use on a regular basis [6].
EMLA (Lidocaine-Prilocaine 5% cream), a widely used
anesthetic cream, has a relatively long onset of action (60
minutes), causes local vasoconstriction and is associated
with a risk of methemoglobinemia. These factors limit its
usefulness in newborns. Tetracaine gel (4% w/w tet-
racaine in an aqueous gel, Amethocaine 4% or Ametop,
Smith-Nephew Inc, St-Laurent, Quebec), a topical anes-
thetic developed in the early 1990s, may be a promising
alternative. The onset of action is 30 to 45 minutes and
there is no risk of methemoglobinemia. In addition, it
causes local vasodilatation, which may be an advantage
when it is used prior to central venous catheter placement.
The localized anesthetic action of tetracaine has been
demonstrated after 30 minutes in infants [7]. The evi-
dence supporting the clinical efficacy of tetracaine is
equivocal. Two randomized controlled trials (RCTs)
reported a reduction in pain scores [8,9] and cry duration
[8] during venipuncture and venous cannulation. How-
ever, no benefit could be demonstrated for heel pricks in
a similar population in two other RCTs [10,11]. A recent
randomized trial by Ballantyne et al. [12] did not demon-
strate a benefit of tetracaine for PICC insertions in prema-
ture infants. This trial included infants 27 weeks or
greater.
The evidence is sparse with respect to the efficacy and
safety of tetracaine in preterm infants. For PICC insertions
specifically, the only trial published is the one from Bal-
lantyne et al., who enrolled 49 infants. There is virtually
no evidence about tetracaine for PICC insertion in infants
less than 28 weeks, who represent a great proportion of
those requiring a PICC. These small infants are subjected
to the highest numbers of painful procedures and have
the least energy reserves to mount stress reactions. Preterm
infants are at the highest risk of suffering long-term conse-
quences of repeated painful experiences [4]. The objective
of this study was to evaluate whether the application of
tetracaine 4% before inserting a PICC in newborn infants
would safely and significantly decrease procedural pain as
compared to placebo.
Methods
Participants
Infants admitted to the NICU of The Ottawa Hospital,
General Campus, Ottawa, Canada were eligible for this
study if they required a PICC. The study site is a 25 bed
level 2 and 3 NICU at a metropolitan university-affiliated
hospital. Infants were enrolled if they met the following
inclusion criteria: (a) born at ≥ 24 weeks gestation, (b)
skin considered in good condition (no burns or rash), (c)
if < 27 weeks gestation, at least 48 h of life and (d) consid-
ered stable by the treating neonatologist.
Infants were excluded if they met any of the following cri-
teria: (a) skin considered immature (insensible water
losses requiring more fluids than usual for gestation), (b)
suspected or proven significant central nervous system
anomaly, (c) receiving opioids or sedatives at time of
PICC insertion or in the previous 12 h or receiving muscle
relaxants, (d) facial anomalies (cleft lip, Moebius syn-
drome) preventing typical facial expression of pain or (e)
suboptimal hepatic function (ALT > 2 × upper normal
limit) or suboptimal renal function (urine output < 1 ml/
kg/hour in the 12 hours prior to the study intervention).
The study was approved by the Research Ethics Board of
The Ottawa Hospital. Informed consent was obtained
from a parent or legal guardian for all enrolled infants by
a research assistant or a member of the research team, at
arms-length of clinical care.
Intervention
The study gel was applied to the proposed PICC site by a
nurse 'blind' to group assignment (under the supervision
of the research assistant), 30 minutes prior to the inser-
tion of the PICC. Tetracaine 4% gel was applied to the skin
of each participant allocated to the treatment group; Pro-
fessional Care Lotion (by Smith-Nephew) was applied to
the skin of each participant allocated to the placebo
group. An occlusive dressing (sterile Saran Wrap) was
applied over the gel. Tubes of 1.5 g of tetracaine were
used, of which 1.1 g could be extracted; the dose of gelBMC Medicine 2006, 4:11 http://www.biomedcentral.com/1741-7015/4/11
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applied to the skin was therefore 1.1 g. After 30 minutes,
the gel was removed and the PICC procedure began.
Blinding
The study gel was packaged by a single research pharma-
cist in identical looking ointment jars identified by medi-
cation number, which matched the enrolment number.
Both gels were white, odorless and had the same consist-
ency. Pre-prepared jars containing tetracaine 4% or pla-
cebo gel identified by the medication number were sent to
the NICU and stored in the refrigerator. Once a partici-
pant was enrolled, the next sequential jar was used for the
PICC insertion. The parents, guardians and research team,
including outcome assessors, were blind to treatment
assignment throughout the study. We did not evaluate the
success of our blinding procedure.
Randomization
Infants were randomized with equal probability (1:1) of
being allocated to either placebo or tetracaine 4% gel. The
sequence, a random-permuted block with block size of 4,
was computer-generated by the study statistician. To help
ensure adequate allocation concealment, the computer
sequence was kept centrally on computer and could only
be activated when there was an eligible baby to rand-
omize. The Research Assistant (RA) completed an eligibil-
ity criteria checklist using a personal digital assistant
(PDA). Once an affirmative answer was given to all ques-
tions the RA synchronized the PDA with a desktop com-
puter. This relayed the PDA answers to the central
randomization computer. Upon receipt of an affirmative
answer, the central computer released the group assign-
ment for that infant only. For this trial, the group assign-
ment was given as "baby # 1 to receive jar of gel labeled #
1" and so on in sequential order until all babies were allo-
cated. Only the research pharmacist was aware of the ran-
domization code. The randomization sequence was not
broken until data analysis was completed.
Co-interventions
Where possible, both groups received standard currently-
practiced non-pharmacological measures of non-nutritive
sucking, swaddling and comforting throughout the PICC
insertion procedure, as appropriate for gestation.
Procedure
The PICC (24 Gauge, 1.9 French or 28 Gauge 1.2 French
L-Cath Peel Away System; Luther Medical Inc, Tustin, CA)
was inserted according to a standardized protocol by a
select group of nurses (total of 4) who are certified in
PICC insertion. Data were collected during 5 phases of the
PICC insertion: (1) Application phase – the PICC nurse
examined the skin. She applied the study gel to the appro-
priate antecubital area and an occlusive dressing (sterile
Saran wrap) was applied over the site. After 30 minutes
the dressing and the gel were removed. (2) Baseline – 2
The infant remained undisturbed in a position of comfort
for 1 minute. (3) Preparation–The site was cleansed
according to the PICC protocol. (4) PICC insertion – The
central catheter was inserted according to protocol and a
dressing was then applied. (5) Recovery – The infant was
returned to a position of comfort at which point filming
ceased.
A maximum of three attempts were made to insert the
PICC. If unsuccessful, the procedure was stopped, a dress-
ing was applied at the puncture site and the infant was
returned to his/her previous comfort position. Failed
attempts to insert a PICC were recorded as failures and
data were analyzed according to treatment allocation.
Physiological indicators of pain (heart rate, blood pres-
sure, respiratory rate, oxygen saturation) were continu-
ously recorded using a Hewlett Packard Neonatal Monitor
from the application phase to the recovery phase.
The RA videotaped facial action indicators from baseline
to the end of recovery phase with a Sony 8 mm digital
Camcorder. The total duration of cry from PICC insertion
to recovery was determined from the video camera record-
ings in non-intubated infants. All data were entered on a
personal digital assistant and subsequently uploaded to a
central database.
Outcomes
The primary outcome was the Premature Infant Pain Pro-
file (PIPP) score in the first minute of the PICC insertion
phase. The PIPP was specifically developed to assess acute
pain in preterm and term infants [13]. It has undergone
extensive clinimetric development for procedural pain of
heel-stick, venipuncture, intravenous insertion and cir-
cumcision. Interrater and intrarater reliability analysis for
individual event scores yielded coefficients of 0.93 to 0.96
and 0.94 to 0.98, respectively [13]. One of two trained
facial coders from Dr Bonnie Steven's laboratory at the
Hospital for Sick Children assessed the video camera
recordings of the PICC insertion for three specific vali-
dated facial expressions of pain that are part of the PIPP
score: brow bulge, nasolabial furrow and eye squeeze. The
intrarater and interrater reliability scores of the facial cod-
ers were 0.95 and 0.95 (percent agreement) respectively
during the study (personal communication, Janet
Yamada, February 2005). Coders were blinded to the
group allocation of infants. PIPP scores were calculated by
one investigator (DH) by combining these behavioral
findings with the other components of the PIPP. PIPP
scores were assigned every minute during the PICC proce-
dure, from baseline through to the recovery phase. Using
the tool as it was originally validated, differences in oxy-
gen saturation and heart rate were compared from base-BMC Medicine 2006, 4:11 http://www.biomedcentral.com/1741-7015/4/11
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line to each minute after skin puncture, which marked the
beginning of the insertion phase. Each PIPP score was
derived by calculating two 30-second intervals for each
minute of the procedure. The PIPP score was assigned as
the highest value of the two 30 second scores.
The secondary outcome measures were: (i) PIPP scores
during the second, third and fourth minute of the inser-
tion phase (compared both independently and longitudi-
nally including the observationduring the first minute of
the procedure); (ii) mean heart rate in beats per minute,
respiratory rate per minute, blood pressure in mm Hg and
02 saturation in % at the end of baseline, 1 minute into the
PICC insertion phase, then 2, 3, 4, 5 and 10 minutes into
the insertion phase; (iii) duration of cry, from PICC inser-
tion to recovery; (iv) mean number of attempts required
to insert the PICC, success rate and subjective measure of
ease/difficulty on a scale of 1 to 5 (1 being very easy and
5 very difficult). Ease of insertion was derived by asking
the RN to appraise her assessment of the ease of perform-
ing the procedure.
The safety of tetracaine was appraised using the following
data: local skin reaction (redness, edema), complete
blood count and differential (pre and post intervention),
AST and ALT (pre and post intervention), and creatinine
levels (post intervention). The biochemical measures were
obtained during routine blood sampling in the NICU. All
infants' vital signs were monitored throughout and after
the intervention and any significant event (apnea/brady-
cardia, sustained bradycardia or tachycardia, sustained
desaturation requiring intervention) was recorded and
reported until the recovery phase. All infants were moni-
tored continuously after the procedure and staff was
encouraged to contact the research team if there were any
concerns.
Sample size
The research team had discussions with several NICU col-
leagues who manage infants with pain, focusing on what
magnitude of difference in pain scores they would deem
clinically important between treatment and placebo
group. The consensus was a minimally clinically impor-
tant difference (MCID) of 3 units on the PIPP score (out
of 21 units). The following assumptionswere used: (i) a
minimal clinical important difference of 3 units on pain
score scale; (ii) an estimated standard deviation of 3.2
units on the pain score scale, based on preliminary results
of Ballantyne's trial [12]; (iii) effects of tetracaine may be
better or worse than the placebo (two-sided test); (iv) sta-
tistical power of 90% and a type I error of 5%. With these
assumptions, the expected total sample size necessary to
detect that difference in pain score was 48 patients (24 per
treatment group). To account for potential technical/
equipment problems, 10% was added to the sample size,
thus 54 participants were recruited. [14]
One int7erim analysis was conducted after half of the
patients were enrolled. This analysis focused on the pri-
mary outcome and safety issues. Using the O'Brien-Flem-
ing criteria for two-sided tests, the alpha-level of this
interim analysis was 0.005. The results at that time were
inconclusive and the trial continued to the planned
recruitment target. In the final analysis, differences were
declared statistically significant if the p value was 0.048 or
less.
Statistical analysis
The differences in PIPP scores between groups were
assessed using an independent Student's t-test. Differ-
ences between treatment and control groups in PIPP
scores measured during the first 4 minutes of intervention
were evaluated using an analysis of variance with repeated
measures, adjusting for gender and postnatal age. It has
Table 1: Baseline characteristics of excluded and included participants
Characteristics Excluded (n = 16) Included (n = 53) Difference (95%CI) p-value
Birth weight in grams, mean (sd) 983.1 (242.38) 915.2 (294.29) 67.96 (-93.45, 229.37) 0.406
Completed weeks of gestation, mean (sd) 27.7 (1.99) 27.1 (2.23) 0.66 (-0.58, 1.90) 0.330
Male, n (%) 11 (68.8) 23 (43.4) 25.4 (-2.4, 46.5) 0.093
Participant flow through the various stages of the study Figure 1
Participant flow through the various stages of the study.
Assessed for eligibility
(n=79)
Randomized (n=54)
   Excluded (n=25):
   . Parents declined consent (n=13)
   . Did not meet eligibility criteria (n=9)
   . Research assistant unavailable (n=1)
   . Study drug not available (n=2)
Allocated to Ametop
(n=27)
Allocated to placebo
(n=26)
Included in the analysis
of the primary outcome
(n=23)
Included in the analysis
of the primary outcome
(n=26)
Randomization error
(n = 1)
Event preventing
procedure (n = 1)
Technical difficulties with video
recording (n=3)BMC Medicine 2006, 4:11 http://www.biomedcentral.com/1741-7015/4/11
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been shown that these variables may influence the level of
pain in infants [15].
A Generalized Wilcoxon test was used to assess whether or
not the duration of cry was different for the group receiv-
ing tetracaine 4% gel and the control group. The differ-
ence in number of attempts inserting the PICC was
determined using a Poisson regression model. Ease of
insertion was compared between study groups with a
Mann-Whitney test. Finally, Fisher's exact tests were con-
ducted to assess a difference in success in PICC insertion
and frequency of adverse event. Safety comparisons (local
skin reaction, anomalies on the CBC, liver or renal func-
tion tests) and sequential vital signs for each group were
summarized using descriptive statistics.
Results
Participants were enrolled in the study between December
2002 and July 2004. Seventy-eight infants were assessed
for eligibility during that time, 54 were randomized and
primary outcome data were recorded for 49 of these (Fig-
ure 1). There was one randomization error and primary
outcome was unavailable for 3 infants owing to technical
difficulties with the video recordings. In another infant,
the PICC had to be postponed owing to persistent brady-
cardia after the study drug was applied. Excluded patients
did not differ from included patients in their baseline
characteristics (Table 1).
Baseline characteristics of included infants were similar
between groups (Table 3). The mean PIPP score in the first
minute was 10.88 in the treatment group as compared to
11.74 in the placebo group (p = 0.53). Although the PIPP
scores during the 1st, 2nd, 3rd and 4th minutes were 0.45 to
1.27 units lower in the tetracaine group as compared to
the placebo group, this was not statistically significant
(Table 3). A repeated measures ANOVA, adjusted for gen-
der and age in days, revealed no significant differences in
PIPP scores between groups over the first 4 minutes (p =
0.330). Median duration of crying in non-intubated
infants was 181 (treatment group) versus 68 seconds (pla-
cebo group) (p = 0.771). Ease of insertion of the PICC,
number of attempts and success rates were similar
between groups. Mean heart rate, respiratory rate, mean
oxygen saturation and mean blood pressure at the end of
baseline, 1, 2, 3, 4, 5 and 10 minutes, were similar
between groups (Table 4).
Transient skin erythema was observed in three infants in
the tetracaine group and in one infant in the placebo
group. One infant in the tetracaine group (25 weeks gesta-
tion, 491 g, just over 48 h old) had a sustained bradycar-
dia (heart rate of 80/min) but stable saturation and blood
pressure after insertion of a nasogastric tube while the
study gel was on his skin. The PICC was postponed and
the infant recovered after 45 minutes. No other adverse
events were noted throughout the study. No significant
changes were noted in any patient's CBC, ALT or creati-
nine in either group (Table 5).
Primary clinical validation of the PIPP suggests smaller
infants could have a lower PIPP score [13]. Since a signif-
icant proportion of our population was less than 28 weeks
gestation (n = 35), we conducted a post hoc analysis of the
primary outcome, stratified for gestational age (i.e. less
than 28 weeks or 28 weeks or more). No difference was
found in the sequential PIPP scores, either in the treat-
ment or in the control groups, on the basis of this gesta-
tion cut-off (Figure 2). PIPP scores were slightly higher in
more immature infants by up to 1–2 points.
PIPP scores according to gestational age Figure 2
PIPP scores according to gestational age.
Table 2: Baseline characteristics
Characteristics Placebo (n = 26) Tetracaine (n = 27)
Birth weight in grams, mean (sd) 950.6 (294.94) 881.1 (295.14)
Completed weeks of gestation, mean (sd) 26.9 (2.04) 27.2 (2.43)
Male, n (%) 11 (57.7) 12 (44.4)
Age in days, mean (sd) 6.6 (3.01) 6.8 (3.25)BMC Medicine 2006, 4:11 http://www.biomedcentral.com/1741-7015/4/11
Page 6 of 9
(page number not for citation purposes)
Discussion
In this study, 1.1 g of topical tetracaine 4%, applied to pre-
mature infants 30 minutes before insertion of a PICC, did
not significantly reduce procedural pain as measured by
the PIPP tool. We had sufficient statistical power to detect
at least a 3-unit difference in PIPP scores between the
treatment groups, but less than a third (0.86 units) of this
difference was observed. Despite the statistical result we
believe our findings are relevant for clinicians at the bed-
side, when they deliberate how best to alleviate pain dur-
ing insertion of a PICC in infants.
Two previous trials have evaluated topical anesthetics
before a PICC insertion in infants. In a randomized trial,
Garcia et al. [16] compared EMLA to placebo for percuta-
neous insertions of central venous lines in infants less
than 1500 g. They found that infants in the treatment
group had a smaller increase in their heart rates during the
procedure. No formal pain tool was used and the sample
was small (n = 13). More recently, Ballantyne et al. [12]
evaluated the benefit of 1.0 g of tetracaine in infants 27 to
41 weeks gestation undergoing a PICC insertion. As in our
study, no significant difference in the PIPP scores could be
seen over the first 3 minutes of the procedure. The PIPP
tool was used and the technique to apply a tourniquet (a
sterile rubber catheter) was similar to the one used in this
study. Infants in that study had a mean gestational age of
33 weeks and their PIPP scores overall were 2–23 points
lower than ours.
There are several explanations for the lack of significant
difference between the treatment and the placebo groups.
Like other trials exploring ways to minimize pain in
infants, this study was subject to potential problems
related to the use of assessment processes and tools. Man-
ually coding the videotapes and pain assessment is prob-
ably always open to human error. We conducted random
calibration exercises to re-verify the PIPP scores and tested
inter-rater and intra-rater reliability during the study;
however, some margin of error may have remained.
To our knowledge, we included the smallest and most
immature infants ever enrolled in a randomized control-
led trial involving tetracaine. More than half of our popu-
lation (n = 35) was less than 28 weeks gestation. These
infants are representative of those requiring a PICC in ter-
tiary care centers. However, data are limited on multidi-
mensional pain responses and their assessment in infants
less than 28 weeks gestation. Previous validation data by
Stevens et al. showed more immature infants to have
lower PIPP scores than more mature ones [13]. Only 9
infants less than 28 weeks gestation were included in that
study. Our post hoc analysis of the primary outcome,
stratified for gestational age, demonstrated higher PIPP
scores in infants less than 28 weeks (up to 1 to 2 points)
than in those 28 weeks or greater. This may partly explain
the difference in PIPP scores between our study and Bal-
lantyne's. The PIPP tool continues to undergo clinimetric
testing and is probably going to keep evolving with more
research and use in very preterm infants.
The recommended pediatric dose of tetracaine was used.
The drug was removed from its original package to pre-
serve blinding. There is no specific recommendation from
the manufacturer on how long the drug is active once
removed from the package; however, crystallization
occurs with evaporation of the water-based gel leading to
drug inactivity and should be felt upon application. This
was not observed in our study, but we cannot rule out that
some of the doses of tetracaine may have become inactive.
Biologically, tetracaine blocks the action potential and we
are not aware of a specific reason why it would fail to do
so, even in immature infants whose skin technically could
absorb more medication rather than less. Recent findings
in pharmacogenomics and pharmacogenetics suggest that
individual genetic factors may explain inter-individual
differences in response to medications [17]. We cannot
exclude the possibility that this could be a confounding
variable in the extremely premature population, although
randomization should have limited the impact.
Given the immaturity of enrolled infants and the lack of
safety data in this population, we chose to apply the gel
for 30 minutes only, as did Ballantyne. The recommended
duration of application for venous cannulation is 45 min-
utes. There is evidence from pediatric literature that an
Table 3: Study outcomes
Outcome n Placebo n Tetracaine Difference (95%CI) p-value
PIPP, 1st minute, mean (sd) 23 11.74 (4.73) 26 10.88 (4.70) 0.86 (-1.86, 3.58) 0.530
PIPP, 2nd minute, mean (sd) 23 10.83 (4.59) 25 9.56 (4.34) 1.27 (-1.33, 3.87) 0.331
PIPP, 3rd minute, mean (sd) 22 10.23 (4.65) 25 9.16 (4.32) 1.07 (-1.57, 3.71) 0.419
PIPP, 4th minute, mean (sd) 23 9.65 (3.74) 25 9.20 (4.78) 0.45 (-2.06, 2.96) 0.718
Duration of cry in seconds, median (range) 8 68 (0, 477) 7 181 (0, 944) -78 (-539, 117) 0.771
Ease of insertion, median (range) 26 2 (1, 5) 26 2 (1, 5) 0 (-1, 0) 0.613
Number of attempts, median (range) 26 2 (1, 3) 26 1 (1, 4) 0 (0, 1) 1.000
PICC successfully inserted, n (%) 26 24 (93.3) 26 19 (73.1) 19.2 (-1.9, 39.2) 0.140BMC Medicine 2006, 4:11 http://www.biomedcentral.com/1741-7015/4/11
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increased duration of application leads to better skin
anesthesia [18]. Jain et al. evaluated time to skin anesthe-
sia in infants 27 to 42 weeks gestation and found that
64% had local skin anesthesia after 30 minutes and 72%
after 45 minutes [7]. Applying the gel for 45 minutes may
have improved efficacy and this is a limitation of the
study.
Although tetracaine has been shown effective in children
to prevent the pain associated with venipuncture or
venous cannulation [19-23], subcutaneous vaccination
[24] or Port-a-Cath puncture [25], it has failed to be ben-
eficial for heel pricks in newborn infants [10,11]. A plau-
sible reason is that, for heel pricks, the squeezing of the
heel rather than the skin puncture is the most painful
event. The pain from squeezing would not be affected by
a topical anesthetic. Inserting a PICC requires more than
a simple skin puncture. Infants are restrained, a tourni-
quet is applied and the procedure can last up to 30 min-
utes. It has been demonstrated in previous studies that
handling and immobilization lead to behavioral and
physiological reactivity [26,27]. Thus, the skin puncture is
Table 4: Physiological parameters during the insertion phase
Outcome n Placebo n Tetracaine
BP at 1 minute, mean (sd) 16 48.7 (9.3) 18 44.5 (5.0)
BP at 2 minutes, mean (sd) 17 49.6 (9.9) 20 46.4 (7.7)
BP at 3 minutes, mean (sd) 13 47.4 (9.4) 19 43.1 (6.1)
BP at 4 minutes, mean (sd) 17 45.8 (6.5) 17 43.2 (5.2)
BP at 5 minutes, mean (sd) 15 43.6 (5.4) 19 45.6 (12.9)
BP at 10 minutes, mean 
(sd)
15 46.3 (7.6) 16 43.0 (6.8)
Heart rate at 1 minute, 
mean (sd)
26 162.6 (12.5) 26 162.4 (11.7)
Heart rate at 2 minutes, 
mean (sd)
26 159.8 (17.0) 26 161.3 (9.1)
Heart rate at 3 minutes, 
mean (sd)
26 159.3 (15.2) 26 157.5 (10.7)
Heart rate at 4 minutes, 
mean (sd)
26 156.9 (14.1) 26 157.3 (14.5)
Heart rate at 5 minutes, 
mean (sd)
26 156.4 (13.7) 26 155.2 (10.2)
Heart rate at 10 minutes, 
mean (sd)
21 149.2 (15.6) 19 155.4 (10.2)
O2 sat at 1 minute, mean 
(sd)
25 90.9 (4.9) 26 92.6 (4.2)
O2 sat at 2 minutes, mean 
(sd)
26 91.4 (4.9) 26 92.8 (3.9)
O2 sat at 3 minutes, mean 
(sd)
25 91.3 (5.3) 26 93.2 (3.9)
O2 sat at 4 minutes, mean 
(sd)
26 91.6 (5.4) 26 92.8 (4.8)
O2 sat at 5 minutes, mean 
(sd)
25 92.0 (5.4) 25 92.6 (4.4)
O2 sat at 10 minutes, mean 
(sd)
21 91.7 (8.2) 19 94.0(4.2)
Respiration at 1 minute, 
mean (sd)
26 55.7 (15.9) 26 51.3 (13.9)
Respiration at 2 minutes, 
mean (sd)
26 53.9 (13.1) 26 51.8 (13.0)
Respiration at 3 minutes, 
mean (sd)
26 58.5 (17.5) 26 50.6 (12.7)
Respiration at 4 minutes, 
mean (sd)
26 50.5 (14.5) 26 55.8 (17.6)
Respiration at 5 minutes, 
mean (sd)
26 54.3 (16.8) 26 52.1 (14.3)
Respiration at 10 minutes, 
mean (sd)
20 55.3 (15.6) 17 50.7 (11.5)BMC Medicine 2006, 4:11 http://www.biomedcentral.com/1741-7015/4/11
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unlikely to be the only painful trigger during a PICC pro-
cedure
Our choice of primary outcome (difference of 3 on the
PIPP score) was not based on a pilot study. It appeared
reasonable and clinically meaningful to aim for a differ-
ence of 3. However, Ballantyne et al. [12] could not find a
difference of 2 and sucrose appears to decrease PIPP scores
by about 2 in venipunctures [28]. Tetracaine may simply
not reduce pain in a clinically meaningful way in the very
preterm population undergoing a PICC.
Another possible limitation of the study is that we did not
record the number of painful procedures infants had
undergone before randomization. This has been shown to
influence the intensity of the reaction to pain [1,29]. Both
groups had similar postnatal age and gestational age;
however, the number of painful procedures may have dif-
fered between infants, though this should have been bal-
anced by the randomization.
PIPP scores for infants in our study were in the "moderate
pain" range. As topical anesthetics have not yet been
shown effective, we would advocate that centers inserting
PICCs consider adding a systemic analgesic to their cur-
rent procedural pain relief guideline. Opioids have poten-
tial side effects, such as cardiovascular instability and
urinary retention as well as possibly leading to worse neu-
rodevelopmental outcomes [30], which limit their use on
a regular basis. However, for limited use such as for proce-
dural pain relief, the advantages may outweigh the risks
[31].
No infant enrolled received oral sucrose, as they were too
immature and not on adequate feeding volumes to meet
the eligibility criteria for sucrose according to our policy.
Sucrose has been shown effective in reducing pain related
to heel pricks and venipunctures in infants 25 to 41 weeks
gestation up to 28 days of age [29]. Furthermore, an RCT
demonstrated that sucrose compared favorably with
EMLA in term newborns undergoing a venipuncture [32].
We speculate that sucrose may have helped modulate the
pain, at least in the first few minutes. Some centers in
Europe use sucrose more liberally in extremely immature
infants and report no adverse effect (personal communi-
cation, R. Carbajal, May 2005). Sucrose may be an adjunct
or alternative to consider in infants undergoing a PICC
insertion.
Conclusion
Tetracaine 4%, when applied for 30 minutes, was not ben-
eficial in decreasing procedural pain associated with a
PICC in very small infants. A longer application time of
tetracaine should be considered in future trials. Future tri-
als should also consider including sucrose into their inter-
vention to decrease pain associated with insertion of a
PICC, even in very immature infants who are not feeding.
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